Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States

Autor: Mickaël Hiligsmann, Stuart S. Silverman, Andrea J. Singer, Leny Pearman, Jake Mathew, Yamei Wang, John Caminis, Jean-Yves Reginster
Přispěvatelé: RS: CAPHRI - R2 - Creating Value-Based Health Care, Health Services Research
Rok vydání: 2023
Předmět:
Zdroj: Pharmacoeconomics, 41(7), 819-830. Adis International Ltd
ISSN: 1179-2027
1170-7690
DOI: 10.1007/s40273-023-01270-x
Popis: Background and ObjectivesAbaloparatide (ABL) significantly increases bone mineral density in men with osteoporosis similar to what was reported in postmenopausal women with osteoporosis. The cost effectiveness of sequential treatment with ABL followed by alendronate (ALN) in men at high fracture risk was compared to relevant alternative treatments.MethodsA Markov-based microsimulation model based on a lifetime US healthcare decision maker perspective was developed to evaluate the cost (expressed in US$2021) per quality-adjusted life-years (QALYs) gained of sequential ABL/ALN. Comparators were sequential treatment unbranded teriparatide (TPTD)/ALN, generic ALN monotherapy, and no treatment. Discount rates of 3% were used. Consistent with practice guidelines, patients received 18 months of ABL or TPTD followed by ALN for 5 years, or 5 years of ALN monotherapy. Analyses were conducted in high-risk men aged over 50 years defined as having a bone mineral density T-score = 60 years.ConclusionsSequential therapy using ABL/ALN may be cost effective compared with generic ALN monotherapy in US men aged >= 50 years at high fracture risk, especially in those aged >= 60 years. Unbranded TPTD/ALN and no treatment were dominated interventions (less QALY, more costs) compared with ABL/ALN or ALN monotherapy.
Databáze: OpenAIRE
Externí odkaz: